198 related articles for article (PubMed ID: 30692637)
21. Breast cancer VPAC1 receptors.
Moody TW; Jensen RT
Ann N Y Acad Sci; 2006 Jul; 1070():436-9. PubMed ID: 16888206
[TBL] [Abstract][Full Text] [Related]
22. Spatial approximation between the C-terminus of VIP and the N-terminal ectodomain of the VPAC1 receptor.
Ceraudo E; Tan YV; Couvineau A; Lacapere JJ; Laburthe M
Ann N Y Acad Sci; 2006 Jul; 1070():180-4. PubMed ID: 16888162
[TBL] [Abstract][Full Text] [Related]
23. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
24. Expression of vasoactive intestinal peptide and related receptors in overcirculation-induced pulmonary hypertension in piglets.
Vuckovic A; Rondelet B; Brion JP; Naeije R
Pediatr Res; 2009 Oct; 66(4):395-9. PubMed ID: 19581838
[TBL] [Abstract][Full Text] [Related]
25. Synaptic scaffolding molecule binds to and regulates vasoactive intestinal polypeptide type-1 receptor in epithelial cells.
Gee HY; Kim YW; Jo MJ; Namkung W; Kim JY; Park HW; Kim KS; Kim H; Baba A; Yang J; Kim E; Kim KH; Lee MG
Gastroenterology; 2009 Aug; 137(2):607-17, 617.e1-4. PubMed ID: 19642226
[TBL] [Abstract][Full Text] [Related]
26. Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells.
Lara-Marquez M; O'Dorisio M; O'Dorisio T; Shah M; Karacay B
J Immunol; 2001 Feb; 166(4):2522-30. PubMed ID: 11160313
[TBL] [Abstract][Full Text] [Related]
27. VPAC1 overexpression is associated with poor differentiation in colon cancer.
Liu S; Zeng Y; Li Y; Guo W; Liu J; Ouyang N
Tumour Biol; 2014 Jul; 35(7):6397-404. PubMed ID: 24671823
[TBL] [Abstract][Full Text] [Related]
28. Vasoactive intestinal peptide (VIP) receptor expression in monocyte-derived macrophages from COPD patients.
Burian B; Storka A; Marzluf BA; Yen YC; Lambers C; Robibaro B; Vonbank K; Mosgoeller W; Petkov V
Peptides; 2010 Apr; 31(4):603-8. PubMed ID: 20026142
[TBL] [Abstract][Full Text] [Related]
29. Upregulation of intestinal mucosal mast cells expressing VPAC1 in close proximity to vasoactive intestinal polypeptide in inflammatory bowel disease and murine colitis.
Casado-Bedmar M; Heil SDS; Myrelid P; Söderholm JD; Keita ÅV
Neurogastroenterol Motil; 2019 Mar; 31(3):e13503. PubMed ID: 30407703
[TBL] [Abstract][Full Text] [Related]
30. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
31. The human VPAC1 receptor: identification of the N-terminal ectodomain as a major VIP-binding site by photoaffinity labeling and 3D modeling.
Couvineau A; Tan YV; Ceraudo E; Lacapère JJ; Murail S; Neumann JM; Laburthe M
Ann N Y Acad Sci; 2006 Jul; 1070():205-9. PubMed ID: 16888167
[TBL] [Abstract][Full Text] [Related]
32. VIP and PACAP analogs regulate therapeutic targets in high-risk neuroblastoma cells.
de Boisvilliers M; Perrin F; Hebache S; Balandre AC; Bensalma S; Garnier A; Vaudry D; Fournier A; Festy F; Muller JM; Chadéneau C
Peptides; 2016 Apr; 78():30-41. PubMed ID: 26826611
[TBL] [Abstract][Full Text] [Related]
33. Vasoactive intestinal polypeptide (VIP) and VPAC1 receptor in adult human dental pulp in relation to caries.
El Karim IA; Lamey PJ; Ardill J; Linden GJ; Lundy FT
Arch Oral Biol; 2006 Oct; 51(10):849-55. PubMed ID: 16806045
[TBL] [Abstract][Full Text] [Related]
34. Role of VPAC1 and VPAC2 in VIP mediated inhibition of rat pulmonary artery and aortic smooth muscle cell proliferation.
St Hilaire RC; Murthy SN; Kadowitz PJ; Jeter JR
Peptides; 2010 Aug; 31(8):1517-22. PubMed ID: 20452385
[TBL] [Abstract][Full Text] [Related]
35. Altered expression of vasoactive intestinal peptide receptors in T lymphocytes and aberrant Th1 immunity in multiple sclerosis.
Sun W; Hong J; Zang YC; Liu X; Zhang JZ
Int Immunol; 2006 Dec; 18(12):1691-700. PubMed ID: 17077178
[TBL] [Abstract][Full Text] [Related]
36. Serine 447 in the carboxyl tail of human VPAC1 receptor is crucial for agonist-induced desensitization but not internalization of the receptor.
Marie JC; Rouyer-Fessard C; Couvineau A; Nicole P; Devaud H; El Benna J; Laburthe M
Mol Pharmacol; 2003 Dec; 64(6):1565-74. PubMed ID: 14645688
[TBL] [Abstract][Full Text] [Related]
37. Vasoactive intestinal peptide/pituitary adenylate cyclase activating polypeptide, and their receptors and cancer.
Moody TW; Nuche-Berenguer B; Jensen RT
Curr Opin Endocrinol Diabetes Obes; 2016 Feb; 23(1):38-47. PubMed ID: 26702849
[TBL] [Abstract][Full Text] [Related]
38. Anti-hyperglycemic, antioxidant and anti-inflammatory effects of VIP and a VPAC1 agonist on streptozotocin-induced diabetic mice.
Yu R; Zhang H; Huang L; Liu X; Chen J
Peptides; 2011 Feb; 32(2):216-22. PubMed ID: 21129425
[TBL] [Abstract][Full Text] [Related]
39. A lymphocyte-generated fragment of vasoactive intestinal peptide with VPAC1 agonist activity and VPAC2 antagonist effects.
Summers MA; O'Dorisio MS; Cox MO; Lara-Marquez M; Goetzl EJ
J Pharmacol Exp Ther; 2003 Aug; 306(2):638-45. PubMed ID: 12750439
[TBL] [Abstract][Full Text] [Related]
40. RNA interference-directed silencing of VPAC1 receptor inhibits VIP effects on both EGFR and HER2 transactivation and VEGF secretion in human breast cancer cells.
Valdehita A; Carmena MJ; Bajo AM; Prieto JC
Mol Cell Endocrinol; 2012 Jan; 348(1):241-6. PubMed ID: 21896307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
